Dapagliflozin May Be Cost-Effective for Treating CKD

FRIDAY, Nov. 4, 2022 (HealthDay News) -- Dapagliflozin seems to be cost-effective in the United Kingdom, Germany, and Spain for patients meeting the eligibility criteria for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, according to a study published online Nov. 2 in the Clinical Journal of the American Society

Related Keywords

Germany ,United States ,United Kingdom ,Spain ,American ,Phil Mcewan ,Astrazeneca ,Health Economics ,Outcomes Research In Cardiff ,Healthday News ,Adverse Outcomes ,Chronic Kidney Disease ,Clinical Journal ,American Society ,Outcomes Research ,